CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy
Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced that its sponsor client, CellVax Therapeutics Inc., received clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for FK-PC101. Patient…
Clarity and PSI kick off SAR-bisPSMA Phase III
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG (“PSI”), a global contract research organisation committed to on-time enrollment…
Prostate Cancer Diagnosis Just Got Easier with CE Mark Certification of Lucida Medical’s New AI Software
Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™). Built with leading clinicians and UK NHS hospitals, the CE mark means the software can…
Hope for Prostate Cancer Patients: Avenda Health’s Unfold AI Enables Precise Cancer Mapping
There is newfound hope for prostate cancer patients as Avenda Health introduces Unfold AI, an innovative technology that employs machine learning to accurately map the extent of prostate cancer. Unfold AI’s ground-breaking 3D visualization technique ensures physicians can formulate personalized…
